Related Experiment Video

Updated: Jul 22, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

A comparison of digoxin and dobutamine in patients with acute infarction and cardiac failure

R A Goldstein, E R Passamani, R Roberts

    The New England Journal of Medicine
    |October 9, 1980
    PubMed

    Insights

    Dobutamine significantly improved cardiac output and reduced pulmonary congestion in heart failure patients post-myocardial infarction. Digoxin showed minimal hemodynamic effects, highlighting dobutamine

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Acute myocardial infarction (AMI) can lead to cardiac failure.
    • Hemodynamic support is crucial in early AMI management.

    Purpose of the Study:

    • To compare the hemodynamic effects of dobutamine and digoxin in patients with early cardiac failure post-AMI.
    • To evaluate the impact of these drugs on cardiac output, filling pressures, and vascular resistance.

    Main Methods:

    • Six patients with cardiac failure within 24 hours of AMI were studied.
    • Intravenous dobutamine was administered, followed by intravenous digoxin after hemodynamic stabilization.
    • Hemodynamic parameters including cardiac index, filling pressure, and systemic vascular resistance were measured.

    Main Results:

    • Dobutamine significantly decreased left ventricular filling pressure and systemic vascular resistance.
    • Dobutamine increased cardiac index and stroke work index without altering heart rate or arterial pressure.
    • Digoxin demonstrated minimal effects on filling pressure, cardiac index, and stroke work index.

    Conclusions:

    • Dobutamine effectively enhances cardiac output and reduces pulmonary congestion in early cardiac failure post-AMI.
    • Digoxin had limited impact on preload and afterload in this patient cohort.
    • Dobutamine represents a more potent therapeutic option for acute hemodynamic support in this setting.

    More Related Videos

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft05:25

    Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

    Published on: September 15, 2023

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...